Nivolumab treatment in melanoma patients has manageable safety profile

Related posts:

1. Queensland becomes home to first all-Australian skeleton library A university in Brisbane opens the first all-Australian skeleton library in the country allowing students to study a 'typical Aussie' skeleton....
2. Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015 CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill....
3. Smoking legislation prevents more than 11,000 child hospital admissions in England each year The introduction of smoke-free legislation in England was associated with over 11,000 fewer admissions to hospital a year from respiratory infections in children, according to a new study....
4. Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences--and so preventing mutations--are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability....
5. SDSU researchers awarded NIH grant to understand how autism plays out across the lifespan In the public consciousness, autism spectrum disorder only affects children. In truth, ASD is a lifelong condition. But how it affects older adults is a gaping unknown in autism research. Now, a new and significant grant from the National Institutes of Health will help researchers at San Diego State University understand how the disorder plays out across the lifespan....